Literature DB >> 24475427

Lipoprotein (a): More than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment.

Ali Ghorbani1, Mahmoud Rafieian-Kopaei2, Hamid Nasri3.   

Abstract

BACKGROUND: Hypertension (HTN) is a very common disorder with a substantial impact on public health because of its complications.
OBJECTIVES: To study the association of serum lipoprotein(a) [Lp(a)] elevation with essential hypertension (eHTN). PATIENTS AND METHODS: This study was conducted on a group of essential hypertensive patients. Laboratory exams consisting of serum creatinine and Lp(a) were measured.
RESULTS: Ninety five essential hypertensive patients were enrolled to the study. Serum LP (a) in patients was 46.5±20. In patients an inverse correlation between serum Lp(a) andcreatinine clearance was seen (r = -0.175 p<0.05). There was a significant correlation between serum Lp(a) and age (r =0.191 p<0.05) or duration of HTN (known duration of hypertension period) (r =0.362 p<0.05).
CONCLUSIONS: Our data suggest that Lp(a) may be involved as a cofactor in essential hypertension, with a mechanism that remains to be elucidated.

Entities:  

Keywords:  Essential hypertension; Lipoprotein (a); Renal failure

Year:  2013        PMID: 24475427      PMCID: PMC3886175          DOI: 10.5812/nephropathol.9092

Source DB:  PubMed          Journal:  J Nephropathol        ISSN: 2251-8363


  7 in total

1.  Lipoprotein(a) and atherosclerosis.

Authors:  S Ishibashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-01       Impact factor: 8.311

Review 2.  Under pressure: the search for the essential mechanisms of hypertension.

Authors:  Thomas M Coffman
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension.

Authors:  L A Sechi; F Kronenberg; S De Carli; E Falleti; L Zingaro; C Catena; G Utermann; E Bartoli
Journal:  JAMA       Date:  1997-06-04       Impact factor: 56.272

4.  Lp(a) in hypertensive patients.

Authors:  M Catalano; E Perilli; G Carzaniga; F Colombo; M Carotta; S Andreoni
Journal:  J Hum Hypertens       Date:  1998-02       Impact factor: 3.012

5.  Relationship between lipoprotein(a) levels, oxidative stress, and blood pressure levels in patients with essential hypertension.

Authors:  R Antonicelli; R Testa; A R Bonfigli; C Sirolla; C Pieri; M Marra; S M Marcovina
Journal:  Clin Exp Med       Date:  2001-09       Impact factor: 3.984

6.  Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension.

Authors:  C Gazzaruso; P Buscaglia; A Garzaniti; G Bonetti; S Savino; S Mariotti; A Jucci; G Finardi; D Geroldi
Journal:  J Cardiovasc Risk       Date:  1996-04

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

  7 in total
  7 in total

Review 1.  Lipoprotein (a) and Hypertension.

Authors:  Natalie C Ward; Janis M Nolde; Justine Chan; Revathy Carnagarin; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2021-12-09       Impact factor: 5.369

Review 2.  Biomarkers in hypertension and their relationship with myocardial target-organ damage.

Authors:  Yang Xue; Navaid Iqbal; Jeffrey Chan; Alan Maisel
Journal:  Curr Hypertens Rep       Date:  2014-12       Impact factor: 5.369

3.  Association of vitamins, minerals, and lead with Lipoprotein(a) in a cross-sectional cohort of US adults.

Authors:  Eric J Brandt; Daniel J Brandt; Nihar R Desai; Erica S Spatz; Khurram Nasir; Arya Mani
Journal:  Int J Vitam Nutr Res       Date:  2021-05-24       Impact factor: 1.784

Review 4.  New concepts in nutraceuticals as alternative for pharmaceuticals.

Authors:  Hamid Nasri; Azar Baradaran; Hedayatollah Shirzad; Mahmoud Rafieian-Kopaei
Journal:  Int J Prev Med       Date:  2014-12

5.  A double blind clinical trial on the efficacy of honey drop in vernal keratoconjunctivitis.

Authors:  Ali Salehi; Solmaz Jabarzare; Mohammadreza Neurmohamadi; Soleiman Kheiri; Mahmoud Rafieian-Kopaei
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-24       Impact factor: 2.629

Review 6.  Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants.

Authors:  Azar Baradaran; Hamid Nasri; Mahmoud Rafieian-Kopaei
Journal:  J Res Med Sci       Date:  2014-04       Impact factor: 1.852

Review 7.  Diabetes mellitus and renal failure: Prevention and management.

Authors:  Hamid Nasri; Mahmoud Rafieian-Kopaei
Journal:  J Res Med Sci       Date:  2015-11       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.